Dergiler / Turkish Journal of Gastroenterology / 2018 / Cilt: 29 - Sayı: 5

Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized stud

Sayfa
549–554
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Adverse effects and compliance were not significantly different among the three groups.Conclusion: Neither 10 d of ST nor 14 d of TT achieved the optimum H. pylori eradication rate

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/Aims: The aim of the present study was to compare between the efficacy and tolerability of a sequential therapy (ST) as the first-line treatment for adults with Helicobacter pylori infection and that of standard triple therapy (TT).Materials and Methods: This was a prospective, randomized open-label, single-center study.
📊
Temel Bulgular & Veri:We enrolled 206 patients who were divided into the following three treatment groups: Group A (pantoprazole 40 mg bid (twice daily), amoxicillin 1 g bid, and clarithromycin 500 mg bid for 10 d), Group B (the same TT as Group A for 14 d), and Group C (pantoprazole 40 mg bid and amoxicillin 1 g bid for 5 d, followed by pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for additional 5 d).Results: Intention-to-treat (ITT) analysis revealed that 14 d of TT achieved a higher eradication rate than 10 d of ST (54.8% vs. 50.7%), but the difference was not statistically significant (p=0.623); further, 10 d of TT achieved 45% eradication rate.
💡
Sonuç & Katkı:Adverse effects and compliance were not significantly different among the three groups.Conclusion: Neither 10 d of ST nor 14 d of TT achieved the optimum H. pylori eradication rate
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Background/Aims: The aim of the present study was to compare between the efficacy and tolerability of a sequential therapy (ST) as the first-line treatment for adults with Helicobacter pylori infection and that of standard triple therapy (TT).Materials and Methods: This was a prospective, randomized open-label, single-center study. We enrolled 206 patients who were divided into the following three treatment groups: Group A (pantoprazole 40 mg bid (twice daily), amoxicillin 1 g bid, and clarithromycin 500 mg bid for 10 d), Group B (the same TT as Group A for 14 d), and Group C (pantoprazole 40 mg bid and amoxicillin 1 g bid for 5 d, followed by pantoprazole 40 mg bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for additional 5 d).Results: Intention-to-treat (ITT) analysis revealed that 14 d of TT achieved a higher eradication rate than 10 d of ST (54.8% vs. 50.7%), but the difference was not statistically significant (p=0.623); further, 10 d of TT achieved 45% eradication rate. Per-protocol (PP) anal-ysis revealed that the success rate for 10 d of ST was more than that for 10 d of TT (70.6% vs. 65%; p=0.571); however, the success rate for 10 d of TT was not statistically different from that for 14 d of TT. The eradication rates achieved in the ITT analysis were lower than those achieved in the PP analysis for 10 (45% vs. 65%) or 14 (54.7% vs. 69%) d of TT or for 10 d of ST (50.7% vs. 70.6%). No statistically significant difference was observed. Adverse effects and compliance were not significantly different among the three groups.Conclusion: Neither 10 d of ST nor 14 d of TT achieved the optimum H. pylori eradication rate

🔖

Bu Makaleye Atıf Yap

ENNKAA, A., Shaath, N., SALAM, A., MOHAMMAD, R. M. (2018). Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized stud. Turkish Journal of Gastroenterology, Cilt: 29 - Sayı: 5, 549–554. https://ajindex.com/articles/410114

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (2)

  1. Alakkari A, Zullo A, O’Connor HJ. Helicobacter pylori and nonmalig- nant diseases. Helicobacter 2011; 16: 33-7. [CrossRef] Chey WD, Wong BC. American College of Gastroenterology guide- line on the management of Helicobacter pylori infection. Am J Gas- troenterol 2007; 102: 1808-25. [CrossRef] Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-81. [CrossRef] IARC Helicobacter pylori Working Group. Helicobacter pylori Erad- ication as a Strategy for Preventing Gastric Cancer, International Agency for Research on Cancer, Lyon, France: 2014. IARC Working Group Reports No: 8. Carneiro F. Stomach cancer. In: Stewart B, Wild C, editors. World Cancer Report. International Agency for Research on Cancer, Lyon, France; 2014: 383-91.
  2. Fuccio L, Minardi ME, Zagari RM, Grilli D, Magrini N, Bazzoli F. Me- ta-analysis: Duration of First-Line Proton-Pump Inhibitor-Based Triple Therapy for Helicobacter pylori. Ann Intern Med 2007; 147: 553-62. [CrossRef] Meyer JM, Silliman NP, Wang W, et al. Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori an- timicrobial resistance partnership (SHARP) study, 1993-1999. Ann Intern Med 2002; 136: 13-24. [CrossRef] Malfertheiner P, Megraud F, O’morain C, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut 2017; 66: 6-30. [CrossRef] Gatta L, Vakil N, Vaira D, Scarpignato C. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analy- sis of sequential therapy. BMJ 2013; 347: f4587. [CrossRef] Zullo A, Vaira D, Vakil N, et al. High eradication rates of Helico- bacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003; 17: 719-26. [CrossRef] Vaira D, Zullo A, Vakil N, et al. Sequential Therapy versus Standard Triple-Drug Therapy for Helicobacter pylori EradicationA Random- ized Trial. Ann Internal Med 2007; 146: 556-63. [CrossRef] Gisbert JP, Calvet X, O’connor A, Mégraud F, O’morain CA. Se- quential therapy for Helicobacter pylori eradication: a critical review. J Clin Gastroenterol 2010; 44: 313-25. [CrossRef] Jafri NS, Hornung CA, Howden CW: Meta-analysis. sequential therapy appears superior to standard therapy for Helicobacter pylori infection in patients naive to treatment. Ann Intern Med 2008; 148: 923-31. [CrossRef] Alsohaibani F, Al Ashgar H, Al Kahtani K, et al. Prospective